Clinical Trials Logo

Calcinosis clinical trials

View clinical trials related to Calcinosis.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT01922804 Active, not recruiting - Clinical trials for Metabolic Bone Disorder

Investigations of the Effect of MK-7 on Bone and Glucose Metabolism and Arterial Calcification

K2vita
Start date: July 2013
Phase: N/A
Study type: Interventional

The aims of the present study are to investigate the effect of vitamin K2 on bone turnover, bone mass, bone structure, glucose metabolism, and arteriosclerosis. Osteoporosis, diabetes, metabolic syndrome and cardiovascular disease are common diseases that affect large groups of people in the Western world. Our hypotheses is that vitamin K2 (MK-7) reduces undercarboxylated osteocalcin in postmenopausal women and reduces bone turnover and increases bone mineral density; increases insulin sensitivity and decreases indices of arterial calcification.

NCT ID: NCT01002157 Active, not recruiting - Clinical trials for Coronary Artery Disease

The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification

VitaK-CAC
Start date: October 2011
Phase: N/A
Study type: Interventional

Both Coronary Artery Calcification (CAC)and its annual progression are a strong predictors of cardiovascular events. The development of arterial calcification results from imbalance between calcification promoting and inhibiting factors. An important inhibitor of calcification is Matrix Gla Protein (MGP): a protein present in the vascular wall where it is synthesized by Vascular Smooth Muscle Cells (VSMC). MGP requires Vitamin K-mediated carboxylation to function properly. Deficiency of Vitamin K has been demonstrated to cause arterial calcification and a diet containing large amounts of Vitamin K2 was associated with lower CAC and cardiovascular risk. In animal studies, active supplementation of Vitamin K2 caused regression of existing arterial calcification. Therefore, the aim of this randomized, double-blind, placebo-controlled clinical trial is to investigate whether daily supplementation of Vitamin K2 (Menaquinone-7) to patients with established CAC will lead to a decreased progression-rate of CAC after 24 months of follow-up in comparison to placebo.